Table 2.

Case Descriptions

		Substance Use Disorders
Patient	Experiencing Home-lessness	Noninjection Drug Use	Injection Drug Use	Alcohol Use Disorder	Indication	Pathogen	Culture Source	Days of Antibiotic Therapy Before Dalbavancina	Inpatient Re-admission, Reason	Emergency Department or Urgent Care Representation, Reason	Clinical Failure or Loss to Follow-up
1	Yes	No	No	Yes	Osteomyelitis, foot	MRSA	Bone	35	No	Yes, foot pain with no evidence of infection	No
2	Yes	No	No	Yes	Osteomyelitis, hand	MRSE, Group A Streptococci	Bone	34	Yes, hand pain, no evidence of infection and alcohol intoxication	Yes, alcohol intoxication with delirium	No
3	Yes	Yes	No	Yes	Complicated bacteremia with septic superficial thrombophlebitis	MSSA	Blood	21	No	No	No
4	Yes	Yes	No	No	Complicated bacteremia with pneumonia	MRSA, Group A Streptococci	Blood, sputum	21	No	No	No
5	Yes	No	Yes	Yes	Bacteremia with septic arthritis, skin abscesses, pyomyositis, and osteomyelitis of the humerus complicated by septic pulmonary emboli concerning for tricuspid valve endocarditis	MRSA	Blood, joint synovial fluid, soft tissue, bone, wound abscess	35	Yes,b MRSA bacteremia with shoulder osteo-myelitis	Yes, fatigue and pain due to assault	Clinical failure
6	No	No	Yes	No	Complicated bacteremia with psoas abscess	MSSA	Blood, wound abscess	27	No	No	Lost to follow-up
7	Yes	No	Yes	No	Bacteremia with left upper extremity abscess	MSSA, S. anginosus	Blood, wound abscess	14	No	Yes, upper respiratory infection	No
8	No	No	Yes	No	Bacteremia with osteomyelitis, left shoulder	MSSA	Blood	35	No	No	No
9	Yes	No	Yes	No	Bacteremia with neck abscess, septic thrombophlebitis, and concern for L4-L5 septic joint facet and epidural phlegmon	MRSA	Blood, wound abscess	28	No	Yes, labial abscess	No
10	Yes	No	Yes	No	Tricuspid valve endocarditis	MSSA	Blood	8c	No	No	Lost to follow-up
11	Yes	No	Yes	No	Uncomplicated bacteremia with gluteal abscess	MSSA	Blood	9	No	No	Lost to follow-up
12	Yes	No	Yes	No	Uncomplicated bacteremia secondary to bilateral upper extremity abscesses	MRSA	Blood, wound abscess	7	Yes, hypoxia	Yes, phlebitis	No
13	Yes	No	Yes	No	Complicated bacteremia with probable septic pulmonary embolism and right-sided endocarditis	MRSA	Blood	21	No	Yes, chest pain	No
14	Yes	No	Yes	No	Uncomplicated bacteremia secondary to cutaneous abscess	MRSA	Blood	7	No	No	No
15	No	No	Yes	No	Tricuspid valve endocarditis with septic thrombophlebitis of right external jugular	MRSA	Blood	35	No	No	Lost to follow-up
16	Yes	No	Yes	No	Uncomplicated bacteremia secondary to purulent cellulitis	MSSA	Blood	7	No	Yes, wound check	No
17	No	Yes	Yes	No	Bacteremia with tricuspid valve endocarditis complicated by acute pacer lead infection status postextraction	MRSA	Blood	35	No	No	No
18	No	Yes	No	No	Bacteremia with sternomanubrial septic arthritis and osteomyelitis	MSSA	Blood	35	No	No	No
19	No	No	Yes	No	Uncomplicated bacteremia with cellulitis, foot	MSSA	Blood	7	No	No	No
20	No	No	No	Yes	Complicated bacteremia of unknown source	MSSA	Blood	21	No	No	No
21	No	Yes	No	No	Bacteremia with necrotizing pneumonia with pleural effusion and septic emboli suggestive of right-sided endocarditis	MRSA	Blood, sputum	21	No	Yes, left-sided Bell’s palsy	No
22	Yes	Yes	Yes	No	Tricuspid-valve endocarditis status post–valve replacement	MRSA, E. durans or hirae, alpha-hemolytic Streptococci	Blood	35	No	No	No
23	No	No	No	No	Uncomplicated bacteremia secondary to abscess, left buttock	MSSA	Blood	6	No	No	No
24	Yes	No	Yes	No	Bacteremia with aortic valve endocarditis status post–valve replacement complicated by multiple septic emboli	MRSA	Blood	35	Yes, presyncope and dizziness, urinary tract infection	No	No
25	No	No	No	Yes	Bacteremia of unknown source	MSSA	Blood	14	No	No	No
26	No	Yes	Yes	No	Uncomplicated bacteremia secondary to cellulitis, left lower extremity	MSSA	Blood	7	No	Yes, upper respiratory tract infection	No
27	No	No	Yes	No	Bacteremia with tricuspid valve endocarditis complicated by septic emboli likely secondary to abscess, right upper extremity	MRSA	Blood	35	No	No	No

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; MSSA, methicillin-susceptible Staphylococcus aureus.

^aAfter clearance of blood cultures or appropriate surgical source control.

^bPatient was readmitted 60 days after dalbavancin administration with MRSA bacteremia and shoulder osteomyelitis in the setting of continued injection drug use. During the initial encounter, the patient had received 50 days of parenteral antibiotics (35 days with regards to when source control was achieved). The patient did not show up to the infectious diseases clinic appointment but did show up to a primary care provider appointment, and there was documentation of no concern of infection recurrence. The patient also had multiple emergency department encounters between the discharge date and the subsequent readmission, with normal laboratory tests and imaging not suggestive of infection.

^cThe patient had received 2 weeks of parenteral therapy at an outside hospital before being transferred to Denver Health Medical Center.